Approach

Active substances

To contribute to good health and longer life expectancy.

Valbiotis has adopted a pioneering approach to the prevention of metabolic and cardiovascular diseases by developing a new class of health nutrition products designed to reduce risk factors for which no satisfactory medical solution exists today. These innovative plant-based products are intended for people at risk of developing type 2 diabetes, NASH (non-alcoholic steatohepatitis) or cardiovascular diseases.
From a medical point of view, Valbiotis’s active substances can be integrated into an overall preventive treatment, in addition to existing recommendations for a healthy lifestyle and diet.

Multi-target modes of action

An innovative plant-based strategy.

Valbiotis develops active substances that can simultaneously act on different physiological targets of interest. Thanks to their many pharmacological properties, plants are a perfect resource for this strategy: each plant in a given species is composed of a series of distinct active molecules known as the “totum”, which is obtained by extraction.
To harness the potential of plants, Valbiotis has developed specific, cutting-edge expertise in a range of fields such as plant-based chemistry, biochemistry, bioengineering and the pathophysiology of metabolic disorders.

Clinical evidence

To develop plant-based active substances according to clinical standards.

All our preclinical studies are conducted on specific metabolic disease models and cell cultures to achieve a proof of concept and characterize the modes of action of the active substances.
Clinical plans are then drawn up with a view to ensuring the safety of the products and unequivocally demonstrate their efficacy in reducing the risk factors for major metabolic diseases.
The purpose of clinical development: to obtain specific health claim authorizations for each product from regulatory authorities such as the FDA (the Food and Drug Administration in United States) and the EFSA (the European Food Safety Authority in Europe) or other authorities, depending on the country, which constitute a guarantee of clinical efficacy.